Douglas Krakower, MD

The benefits of addressing barriers and increasing access to HIV PrEP therapies to high-risk populations across the globe.

Types of patients who will likely benefit from long-acting injectable PrEP therapies in the HIV treatment pipeline.

Strategies that can help address disparities in care for patients with HIV and reach high-risk groups of patients to ensure access to screening and PrEP.

Payer perspective regarding strategies that can be deployed to help improve the patient/provider experience and utilization of PrEP therapy as prophylaxis against HIV.

The financial burden associated with HIV and the potential effects of PrEP uptake on overall costs of care.

Considerations to help identify and increase utilization of PrEP therapy among patients who are eligible for treatment.